CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Aridis Pharmaceuticals, Inc. - ARDSus CFD

0.3090
21.99%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0059
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02629 %
Charges from full value of position ($-5.00)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02629%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004068 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004068%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 0.2533
Open 0.294
1-Year Change -72.26%
Day's Range 0.2635 - 0.312
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 18, 2023 0.3090 0.0041 1.34% 0.3049 0.3209 0.2601
Jul 17, 2023 0.2533 -0.0607 -19.33% 0.3140 0.3166 0.2491
Jul 14, 2023 0.3153 -0.0302 -8.74% 0.3455 0.3455 0.3090
Jul 13, 2023 0.3490 0.0454 14.95% 0.3036 0.3588 0.2790
Jul 12, 2023 0.3289 -0.0499 -13.17% 0.3788 0.3987 0.3153
Jul 11, 2023 0.2606 0.0114 4.57% 0.2492 0.2669 0.2490
Jul 10, 2023 0.2617 0.0227 9.50% 0.2390 0.2638 0.2390
Jul 7, 2023 0.2491 0.0257 11.50% 0.2234 0.2502 0.2234
Jul 6, 2023 0.2263 0.0046 2.07% 0.2217 0.2321 0.2213
Jul 5, 2023 0.2272 0.0080 3.65% 0.2192 0.2332 0.2192
Jul 3, 2023 0.2148 0.0006 0.28% 0.2142 0.2259 0.2142
Jun 30, 2023 0.2144 -0.0025 -1.15% 0.2169 0.2169 0.1993
Jun 29, 2023 0.2129 0.0037 1.77% 0.2092 0.2167 0.2092
Jun 28, 2023 0.2116 -0.0276 -11.54% 0.2392 0.2392 0.2092
Jun 27, 2023 0.2413 -0.0088 -3.52% 0.2501 0.2531 0.2345
Jun 26, 2023 0.2492 -0.0099 -3.82% 0.2591 0.2591 0.2491
Jun 23, 2023 0.2597 0.0051 2.00% 0.2546 0.2603 0.2492
Jun 22, 2023 0.2566 -0.0025 -0.96% 0.2591 0.2591 0.2541
Jun 21, 2023 0.2565 0.0043 1.70% 0.2522 0.2601 0.2501
Jun 20, 2023 0.2552 -0.0014 -0.55% 0.2566 0.2671 0.2516

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Aridis Pharmaceuticals, Inc. Company profile

About Aridis Pharmaceuticals Inc

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's proprietary product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), cystic fibrosis and COVID-19. The Company's lead product candidate, AR-301, targets the alpha toxin produced by gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. Its clinical development activities are focused on AR-301, AR-712, and AR-501. Its development of antibody discovery and production platform technology called aPEXTM extends the capabilities of MabIgX, its differentiated antibody discovery platform.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Aridis Pharmaceuticals Inc revenues decreased 45% to $548K. Net loss applicable to common stockholders increased from $16.5M to $37.5M. Revenues reflect License revenue decrease of 87% to $131K. Higher net loss reflects Research and development - Balancing val increase from $12.3M to $28.9M (expense), General and administrative - Balancing increase of 11% to $4.1M (expense).

Industry: Bio Therapeutic Drugs

983 University Avenue, Bldg. B
LOS GATOS
CALIFORNIA 95032
US

People also watch

US100

19,751.00 Price
-0.370% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 7.0

ETH/USD

3,421.70 Price
+0.010% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Gold

2,445.30 Price
-0.550% 1D Chg, %
Long position overnight fee -0.0197%
Short position overnight fee 0.0115%
Overnight fee time 21:00 (UTC)
Spread 0.29

XRP/USD

0.58 Price
-9.220% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading